Back to search

Peptide record

TPDB43292

Anticancer modified_plain modified
7 amino acids
Basic Information
TPDB43292
Anticancer
Cancer-related peptides
CancerPPD 2.0 Peptipedia SATPdb dbACP
modified_plain
Yes
A 7-aa modified anticancer peptide sequence curated from CancerPPD 2.0, Peptipedia, SATPdb, and other sources, without an available 3D structural model.
Chemical: A* = Cαα -dialkylated glycine (Aaa1,1 )
Sequence
YGGFMA*
Physicochemical Analysis
C30H40N6O8S1
RNDCEQHILKPSTWV
G
644.74
5.94
0
0
4
-0
-2.45
0.629
14.29
Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min
1490
231.10
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
0
I
0
L
0
K
1
M
1
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 0 K: 0 M: 1 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
7
C30H40N6O8S1
644.74
5.94
-0
-2.45
0.629
Free
A* = Cαα -dialkylated glycine (Aaa1,1 )
L
Linear
Free
Antitumor
Synthetic Peptide
Evidence Records 13 records
Evidence 1 Activity

Activity

3.9% inhibition at 10-5M
Anticancer

Target

Larynx Cancer
HEp-2
Larynx

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

45% inhibition at 10-3M
Anticancer

Target

Larynx Cancer
HEp-2
Larynx

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 3 Activity

Activity

9.3% inhibition at 10-3M
Anticancer

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 4 Activity

Activity

4.1% inhibition at 10-6M
Anticancer

Target

Skin Cancer
HBL
Skin

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 5 Activity

Activity

70.7% inhibition at 10-5M
Anticancer

Target

Skin Cancer
HBL
Skin

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 6 Activity

Activity

34.4% inhibition at 10-3M
Anticancer

Target

Skin Cancer
HBL
Skin

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 7 Activity

Activity

9.2% inhibition at 10-3M
Anticancer

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 8 Activity

Activity

11.08% inhibition at 10-5M
Anticancer

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 9 Activity

Activity

47.0% inhibition at 10-3M
Anticancer

Target

Colon Cancer
CaCo-2
Colon

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 10 Activity

Activity

2.2% inhibition at 10-6M
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 11 Activity

Activity

7.1% inhibition at 10-5M
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 12 Activity

Activity

6.9% inhibition at 10-4M
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 13 Activity

Activity

25.9% inhibition at 10-3M
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
31.92-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006